Skip to main content
Top
Published in: Pathology & Oncology Research 3/2008

01-09-2008 | Original Paper

No Strong Association Between HER-2/neu Protein Overexpression and Gene Amplification in High-grade Invasive Urothelial Carcinomas

Authors: Vildan Caner, Nilay Sen Turk, Fusun Duzcan, N. Lale Satiroglu Tufan, E. Canan Kelten, Sevil Zencir, Yavuz Dodurga, Huseyin Bagci, S. Ender Duzcan

Published in: Pathology & Oncology Research | Issue 3/2008

Login to get access

Abstract

The generation of urothelial carcinoma is caused by the accumulation of various molecular changes, as in most malignancies. There are conflicting data about the status of HER-2/neu oncogene in urothelial carcinomas. The aim of this study was to determine the status of HER-2/neu oncogene in high-grade invasive urothelial carcinoma of urinary bladder both in protein and DNA level. We evaluated HER-2/neu protein overexpression by immunohistochemistry (IHC) and gene amplification by fluorescent in situ hybridization (FISH) and real-time quantitative PCR in paraffin-embedded samples of high-grade invasive urothelial carcinoma obtained from 36 patients. Polysomy 17 was also assessed by FISH. Immunohistochemically, HER-2/neu protein overexpression was observed in 22 (61.1%) tumors (ten tumors with score 3+ and 12 with score 2+). Fourteen of 36 tumors (38.9%) were evaluated as negative (score 0 or 1+). Complete concordance between FISH and the PCR was seen in all of the samples scored as 0 and 1+ by IHC. HER-2/neu gene amplification was observed in three of 27 (11.1%) tumors by FISH (nine samples were non-informative) and in eight of 36 (22.2%) tumors by the PCR. The complete concordance between HER2-2/neu protein overexpression and gene amplification was seen only in three of 27 tumors. Polysomy 17 was seen in nine tumors (33.3%). The results indicated that, in contrast to breast cancer, there was no strong association between HER-2/neu overexpression and gene amplification in invasive urothelial carcinomas, and polysomy 17 was higher in tumors showing HER-2/neu overexpression.
Literature
1.
go back to reference Latif Z, Watters AD, Dunn I et al (2004) HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 40:56–63CrossRefPubMed Latif Z, Watters AD, Dunn I et al (2004) HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 40:56–63CrossRefPubMed
2.
go back to reference Morrison C, Zanagnolo V, Ramirez N et al (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24:2376–2385CrossRefPubMed Morrison C, Zanagnolo V, Ramirez N et al (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24:2376–2385CrossRefPubMed
3.
go back to reference Ross JS, Fletcher JA, Linette GP et al (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307–325CrossRefPubMed Ross JS, Fletcher JA, Linette GP et al (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307–325CrossRefPubMed
4.
go back to reference Schraml P, Kononen J, Bubendorf L et al (1999) Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5:1966–1975PubMed Schraml P, Kononen J, Bubendorf L et al (1999) Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5:1966–1975PubMed
5.
go back to reference Kruger S, Weitsch G, Buttner H et al (2002) Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 21:981–987PubMed Kruger S, Weitsch G, Buttner H et al (2002) Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 21:981–987PubMed
6.
go back to reference Underwood M, Barlett J, Reeves J et al (1995) c-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 55:2422–2430PubMed Underwood M, Barlett J, Reeves J et al (1995) c-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 55:2422–2430PubMed
7.
go back to reference Bartlett J, Mallon E, Cooke T (2003) The clinical evaluation of HER-2 status: which test to use? J Pathol 199:411–417CrossRefPubMed Bartlett J, Mallon E, Cooke T (2003) The clinical evaluation of HER-2 status: which test to use? J Pathol 199:411–417CrossRefPubMed
8.
go back to reference Langner C, Gross C, Rehak P et al (2005) HER2 protein overexpression and gene amplification in upper urinary transitional cell carcinoma: systematic analysis applying tissue microarray technique. Urology 65:176–180CrossRefPubMed Langner C, Gross C, Rehak P et al (2005) HER2 protein overexpression and gene amplification in upper urinary transitional cell carcinoma: systematic analysis applying tissue microarray technique. Urology 65:176–180CrossRefPubMed
9.
go back to reference Bast RCJ, Ravdin P, Hayes DF et al (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865–1878PubMed Bast RCJ, Ravdin P, Hayes DF et al (2001) 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865–1878PubMed
10.
go back to reference Lamy PJ, Nanni I, Fina F et al (2006) Reliability and discriminant validity of HER2 gene amplification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer. Int J Biol Markers 21:20–29PubMed Lamy PJ, Nanni I, Fina F et al (2006) Reliability and discriminant validity of HER2 gene amplification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer. Int J Biol Markers 21:20–29PubMed
11.
go back to reference Edwards RG, Lara PN, Folkins AK et al (2002) Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95:1009–1015CrossRef Edwards RG, Lara PN, Folkins AK et al (2002) Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95:1009–1015CrossRef
12.
go back to reference Kruger S, Weitsch G, Buttner H et al (2002) HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 102:514–518CrossRefPubMed Kruger S, Weitsch G, Buttner H et al (2002) HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 102:514–518CrossRefPubMed
13.
go back to reference Latif Z, Watters AD, Dunn I et al (2003) HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 89:1305–1309CrossRefPubMed Latif Z, Watters AD, Dunn I et al (2003) HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 89:1305–1309CrossRefPubMed
14.
go back to reference Liminez RE, Hussain M, Bianco FJ Jr, et al (2001) HER-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7:2440–2447 Liminez RE, Hussain M, Bianco FJ Jr, et al (2001) HER-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7:2440–2447
15.
go back to reference Simon R, Atefy R, Wagner U et al (2003) HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 107:764–772CrossRefPubMed Simon R, Atefy R, Wagner U et al (2003) HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 107:764–772CrossRefPubMed
16.
go back to reference Sauter G, Moch H, Moore D et al (1993) Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 53(Suppl 10):2199–2203PubMed Sauter G, Moch H, Moore D et al (1993) Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 53(Suppl 10):2199–2203PubMed
17.
go back to reference Gjerdrum LM, Lielpetere I, Rasmussen LM et al (2001) Laser-assisted microdissection of membrane-mounted paraffin sections for polymerase chain reaction analysis: identification of cell populations using immunohistochemistry and in situ hybridization. J Mol Diagn 3:105–110PubMed Gjerdrum LM, Lielpetere I, Rasmussen LM et al (2001) Laser-assisted microdissection of membrane-mounted paraffin sections for polymerase chain reaction analysis: identification of cell populations using immunohistochemistry and in situ hybridization. J Mol Diagn 3:105–110PubMed
18.
go back to reference Persons D, Tubbs R, Cooley LD et al (2006) HER2 fluorescence in situ hybridization. Arch Pathol Lab Med 130:325–331PubMed Persons D, Tubbs R, Cooley LD et al (2006) HER2 fluorescence in situ hybridization. Arch Pathol Lab Med 130:325–331PubMed
19.
go back to reference Bose S, Mohammed M, Shintaku P et al (2001) Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J 7:337–344CrossRefPubMed Bose S, Mohammed M, Shintaku P et al (2001) Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J 7:337–344CrossRefPubMed
20.
go back to reference Wang S, Hossein Saboorian M, Frenkel EP et al (2002) Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 15:137–145CrossRefPubMed Wang S, Hossein Saboorian M, Frenkel EP et al (2002) Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 15:137–145CrossRefPubMed
21.
go back to reference Gallucci M, Guadagni F, Marzano R et al (2005) Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters. J Clin Pathol 58:367–371CrossRefPubMed Gallucci M, Guadagni F, Marzano R et al (2005) Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters. J Clin Pathol 58:367–371CrossRefPubMed
22.
go back to reference Ohta JI, Miyoshi Y, Uemura H et al (2001) Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer. Clin Cancer Res 7:2463–2467PubMed Ohta JI, Miyoshi Y, Uemura H et al (2001) Fluorescence in situ hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer. Clin Cancer Res 7:2463–2467PubMed
23.
go back to reference Hovey RM, Chu L, Balazs M et al (1998) Genetic alterations in primary bladder cancers and their metastases. Cancer Res 58:3555–3560PubMed Hovey RM, Chu L, Balazs M et al (1998) Genetic alterations in primary bladder cancers and their metastases. Cancer Res 58:3555–3560PubMed
24.
go back to reference Kelly ED, Yoder BJ, Stoler M et al (2005) The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast. Am J Surg Pathol 29:1221–1227CrossRef Kelly ED, Yoder BJ, Stoler M et al (2005) The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast. Am J Surg Pathol 29:1221–1227CrossRef
25.
go back to reference Miyamoto H, Kubota Y, Noguchi S et al (2000) c-erbB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55:679–683CrossRefPubMed Miyamoto H, Kubota Y, Noguchi S et al (2000) c-erbB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55:679–683CrossRefPubMed
Metadata
Title
No Strong Association Between HER-2/neu Protein Overexpression and Gene Amplification in High-grade Invasive Urothelial Carcinomas
Authors
Vildan Caner
Nilay Sen Turk
Fusun Duzcan
N. Lale Satiroglu Tufan
E. Canan Kelten
Sevil Zencir
Yavuz Dodurga
Huseyin Bagci
S. Ender Duzcan
Publication date
01-09-2008
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2008
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9027-y

Other articles of this Issue 3/2008

Pathology & Oncology Research 3/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine